On March 22, 2016, Cipla Limited (Cipla or Company) received Tentative Approval (TA) from the United States Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA#206894) for a generic version of Gilead Sciences Inc.’s (Gilead) ATRIPLA (EFAVIRENZ 600mg + EMTRICITABINE 200mg + TENOFOVIR DISOPROXIL FUMARATE 300mg) Tablets, (March 22nd ANDA).